Current Status of Neuroendocrine Tumors with a Special Focus on Diagnosis and Novel Treatments—2nd Edition
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 3839
Special Issue Editor
2. Department of Endocrine Tumors and Sarcomas, Karolinska University Hospital, Solna, Stockholm, Sweden
Interests: neuroendocrine tumors; bronchial carcinoids; peptide receptor radionuclide therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Neuroendocrine tumors are a growing group of tumors, the majority of which malignant, with local or distant metastases at diagnosis. Tumors are divided according to their proliferative rate into grade 1, grade 2, and grade 3 (G1, G2, and G3, respectively). Most tumors are G1 and G2 and hence slow-growing, and patients suffering from such tumors may live for several years. Some tumors, however, are highly proliferative, and patients affected by them have a short survival and poor prognosis. Most G1 and G2 tumors, and some G3 tumors, express somatostatin receptors and may be detected by somatostatin receptor imaging. Diagnostic sensitivity has improved with the introduction of 68Gallium-DOTATOC PET CT. Somatostatin analogues are the main treatment for patients with low proliferative tumors. Other treatments include chemotherapy, PRRT with 177Lutetium-DOTATATE, and targeted therapies, such as Everolimus and Sunitinib, which have led to an improvement in prognosis. The need for newer therapeutic agents is, however, urgent.
This Special Issue will address current knowledge at the epidemiologic, diagnostic, molecular, and therapeutic level, focusing on new diagnostic and therapeutic measures.
Dr. Dan Granberg
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroendocrine tumors
- somatostatin analogues
- PRRT
- chemotherapy
- 68Gallium-DOTATOC
- PET
- CT
- targeted therapies
- mTOR
- inhibitors
- angiogenesis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Pathological Features Associated With Lymph Node Disease in Patients with Appendiceal Neuroendocrine Tumors
Authors: Salvador Rodriguez Franco; Sumaya Ghaffar; Ying Jin; Reed Weiss; Mona Hamermesh; Madeline Thomas; Andrii Khomiak; Lia Roque Assumpção; Toshitaka Sugawara; Oskar Franklin; Richard D Schulick; Steven Ahrendt; Marco Del Chiaro; Martin McCarter; Ana L Gleisner
Affiliation: University of Colorado, USA
Abstract: This study aimed to evaluate the role of pathological features, beyond tumor size, in the risk of lymph node metastasis in appendiceal neuroendocrine tumors. Analyzing data from the national cancer database, we found that among 5,353 cases, 18.8% had lymph node metastasis.
Focusing on tumors smaller than 2cm, a subject of considerable debate in treatment strategies, we identified lymphovascular invasion as one of the strongest predictors of lymph node disease. Interestingly, extension into the subserosa and beyond, a current factor in the staging system, was not a strong predictor. These findings suggest that careful interpretation of pathological features is needed when selecting therapeutic approaches using current staging systems.
Title: From oGTT to MMTT – more than an exchange of letters Mixed Meal Tolerance Test for the diagnosis of spontaneous hypoglycemia
Authors: Jan Adelmeyer; Christian M. Schauer; Peter H. Kann
Affiliation: Facharzt für Innere Medizin
Zusatzbezeichnung Notfallmedizin
Oberarzt im Zentrum für Endokrinologie, Diabetologie & Osteologie
Abstract: The correct diagnosis of spontaneous hypoglycemia has been a major challenge for clinicians for decades. As a potentially life-threatening neuroendocrine tumor, insulinoma is usually unpredictable in its behavior. It is often not always possible to distinguish between fasting and postprandial hypoglycemia, requiring a carbohydrate load in addition to the 72-hour fast. Many physicians still use the prolonged oGTT for this purpose, although it causes diagnostic difficulties. Ease of administration and better standardization are probably the main reasons for this. The MMTT is a useful alternative because it produces more realistic metabolic imbalances and better differentiates between healthy and sick patients. In this article, we compare 200 OGTT data sets with 40 MMTT data sets and show that the MMTT, as we have constructed it, is not only easy to implement in practice, but also diagnostically valuable. The reader is also given tips and tricks on how to use the MMTT in daily clinical practice.
